Bicycle Therapeutics (FRA:50BA) FFO


FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.46
GF Value €12.98
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.46 is trading 73.3% below its estimated GF Value™ of €12.98. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • FFO:
  • GF Value™: €12.98 vs. price of €3.46 (73.3% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.46
Price
€12.98
GF Value